Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2005

View Archived Issues

Comparative in vitro data of doripenem's potent antimicrobial activity / News in Context

Preclinical antidiabetic efficacy of MB-06322, a selective inhibitor of fructose 1,6-bisphosphatase

Muraglitazar improves glycemic control and lipid profile of patients with type 2 diabetes

Vantas not approvable in Canada

Bayer to study longer-acting Kogenate product in phase I

Hexvix NDA submission

Halozyme files IND for Chemophase

FDA agrees to file and review NDA for Fibrillex

Fampridine-SR enters phase III MS study

AVI submits IND for phase Ib study of AVI-4065 for HCV

Ariad opens enrollment for phase II endometrial cancer study of AP-23573

Phase III Crohn's disease study of Tysabri meets endpoints

Novel integrase inhibitors with different pharmacophores discovered

Agents for HIV infection in early development

Various agents for use in the treatment of cancer revealed in recent patents

Update on abatacept in rheumatoid arthritis

New phase I data on APD-125 in insomnia

Faster onset of action reported for AERx iDMS in type 1 diabetes

Temsirolimus shows promise in the treatment of multiple sclerosis

Procyon Biopharma completes acquisition of Bioxalis Medica

EMEA completes review of COX-2 inhibitors

Not approvable letter for tipifarnib

NitroMed launches BiDil

GenPat77 discovers novel protein that regulates immune cell activation

Recent patents described novel dermatologic compounds